Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPV Cross-Reactivity with SARS-CoV-2
NCT04639375Phase 4
Key facts
- Status
- Unknown
- Start
- Nov 2020
- Primary completion
- Jun 2021
- Countries
- 1
- Sponsor
- E-MO Biology Inc.
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Conditions
- coronavirus disease 2019 (COVID-19)
01
Overview
Phase 4, open-label, single-arm trial of trivalent inactivated polio vaccine in coronavirus disease 2019 (COVID-19), sponsored by E-MO Biology Inc. Primary endpoint: Percentage of Subjects with Antibodies to SARS-CoV-2 RdRp following IPV Vaccination at Day 28. Status: unknown.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Vaccinated with polio vaccine (IPV)
Subjects receive a single booster dose of Inactivated Poliovirus Vaccine (IPV)
03
Who it enrols
Healthy volunteers aged 18-80 with no history of COVID-19, no recent febrile illness, and no polio vaccination in the last 12 years.
04
Endpoints
Primary
Percentage of Subjects with Antibodies to SARS-CoV-2 RdRp following IPV Vaccination
Secondary
Determination of neutralizing titer of antibodies raised to SARS-CoV-2
Beyond the preview
Go deeper on NCT04639375.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04639375.